AI summary · may contain errors
In orthotopic hepatocellular carcinoma models, GPC3-targeted paired PET imaging and alpha therapy achieved strong tumor uptake (>200 %IA/g) and excellent local control after a single 9.3 kBq dose.
Moving in European Urology, Clinical Cancer Research, Molecular Cancer Therapeutics, Journal of Clinical Oncology, Annals of Oncology, British Journal of Pharmacology, Gastroenterology and Molecular Therapy.
Rebuilt
Nothing in this topic has moved yet this week.
Newest first · last 60 days
AI summary · may contain errors
In orthotopic hepatocellular carcinoma models, GPC3-targeted paired PET imaging and alpha therapy achieved strong tumor uptake (>200 %IA/g) and excellent local control after a single 9.3 kBq dose.
AI summary · may contain errors
A 68Ga-NOTA-ssDNA PET/CT probe enables early detection of renal immune complex deposition in 10-week-old MRL/lpr lupus mice, preceding conventional renal marker changes by ~2 weeks.
AI summary · may contain errors
In 25 patients with locally advanced/metastatic urothelial carcinoma, [68Ga]Ga-DOTA-N188 PET/CT detected primary tumors with higher specificity (86% vs 57%) than [18F]-FDG PET/CT.
AI summary · may contain errors
Mirvetuximab soravtansine, an FRα-targeting antibody-drug conjugate, has regulatory approval for platinum-resistant ovarian cancer, marking a major clinical milestone for FRα-directed therapy.
AI summary · may contain errors
89Zr-CB307 PET shows selective accumulation in PSMA-positive metastatic castration-resistant prostate cancer lesions, with liver uptake (SUVmean 13.06 ± 2.68 at day 7) and no spleen or marrow uptake.
AI summary · may contain errors
[225Ac]Ac-Macropa-M16AB achieved complete remissions in MUC-16-positive ovarian and pancreatic ductal adenocarcinoma patient-derived xenografts, with 100% sustained CRs in high/medium expressers.
AI summary · may contain errors
PSMA radio-guided surgery during robot-assisted radical prostatectomy with extended pelvic lymph node dissection identified additional pathologically node-positive patients (pN1) missed by preoperative PSMA PET.
AI summary · may contain errors
ADCT-241, a PSMA-targeting exatecan-based antibody-drug conjugate, shows potent, target-dependent antitumor activity in prostate cancer xenografts with a cynomolgus monkey half-life of 8–10 days.
AI summary · may contain errors
Theranostics in oncology integrates diagnostic imaging and radionuclide therapy using matched probes, and clinical progress is linked to a promising future for multiscale approaches.
AI summary · may contain errors
Hypofractionated proton beam therapy (HART) for localized unresectable hepatocellular carcinoma (HCC) and intrahepatic cholangiocarcinoma (ICC) yields median overall survival of 29.2 months and 20.8 months, respectively.
AI summary · may contain errors
In a multicenter phase I study in gastroenteropancreatic well-differentiated neuroendocrine tumors, [177Lu]lutetium-dotatate plus triapine selected 200 mCi with 150 mg as RP2D and showed an objective response rate of 21.4% (28 evaluable patients).
AI summary · may contain errors
In 45 adults with high-relapse-risk myeloid malignancies or acute leukemia, single-infusion 211At-CD45 radioimmunotherapy established 500 μCi/kg as the maximum tolerated dose.
AI summary · may contain errors
Fractionated-dose 225Ac-J591 in metastatic, androgen pathway modulation-resistant prostate cancer shows an RP2D of 60 KBq/kg twice, with DLTs guiding tolerability.
AI summary · may contain errors
Neoadjuvant 177 Lu-PNT2002 before SBRT significantly improved progression-free survival in PSMA PET/CT–detected oligorecurrent hormone-sensitive prostate cancer, with median 17.6 vs 7.4 months.
AI summary · may contain errors
ADCT-241, a PSMA-targeting exatecan-based antibody-drug conjugate, shows potent, target-dependent antitumor activity in prostate cancer xenografts and cell lines.
AI summary · may contain errors
A glycosylated 18F-fluorodeoxyglucose-derived PET tracer selectively incorporates into Staphylococcus via the glucose-specific phosphotransferase transporter and detects live gram-positive infection with >6-fold higher signal than non-infected tissue in mice.
AI summary · may contain errors
PSMA-PET/CT-guided radiotherapy (PSMAgRT) did not improve 5-year failure-free survival overall (66% vs 62%; HR 0.80; p=0.14) in a phase 2 randomized trial.
AI summary · may contain errors
In 10 patients with unresectable or metastatic, treatment-refractory pheochromocytoma or paraganglioma, a single 2.1 MBq/kg dose of 211At-MABG showed no dose-limiting toxicities.
Journals this month
Topics moving, week to 17 Nov 2026
By field